Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) – Analysts at Jefferies Group issued their Q1 2018 earnings per share (EPS) estimates for Amphastar Pharmaceuticals in a research report issued on Tuesday, March 13th, according to Zacks Investment Research. Jefferies Group analyst D. Steinberg anticipates that the company will post earnings of $0.11 per share for the quarter. Jefferies Group also issued estimates for Amphastar Pharmaceuticals’ Q2 2018 earnings at $0.11 EPS, Q3 2018 earnings at $0.13 EPS and Q4 2018 earnings at $0.30 EPS.
Amphastar Pharmaceuticals (NASDAQ:AMPH) last released its quarterly earnings data on Monday, March 12th. The company reported $0.10 EPS for the quarter, topping analysts’ consensus estimates of $0.07 by $0.03. Amphastar Pharmaceuticals had a return on equity of 4.56% and a net margin of 1.88%. The firm had revenue of $60.40 million for the quarter, compared to the consensus estimate of $60.62 million. During the same quarter in the prior year, the company posted $0.01 earnings per share. The firm’s revenue was down 4.9% on a year-over-year basis.
Other equities analysts also recently issued research reports about the company. Wells Fargo restated a “buy” rating on shares of Amphastar Pharmaceuticals in a report on Wednesday, March 21st. Piper Jaffray restated a “buy” rating and issued a $26.00 price objective on shares of Amphastar Pharmaceuticals in a report on Tuesday, January 30th. Needham & Company LLC restated a “buy” rating and issued a $24.00 price objective (up previously from $23.00) on shares of Amphastar Pharmaceuticals in a report on Tuesday, March 13th. Zacks Investment Research raised Amphastar Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, January 2nd. Finally, BidaskClub raised Amphastar Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, February 10th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and four have assigned a buy rating to the stock. Amphastar Pharmaceuticals currently has a consensus rating of “Hold” and an average price target of $21.33.
NASDAQ:AMPH opened at $19.01 on Thursday. Amphastar Pharmaceuticals has a 52 week low of $13.15 and a 52 week high of $20.45. The company has a market capitalization of $881.59, a P/E ratio of 50.03, a PEG ratio of 1.35 and a beta of 1.42. The company has a debt-to-equity ratio of 0.12, a quick ratio of 1.85 and a current ratio of 2.79.
Several institutional investors and hedge funds have recently bought and sold shares of AMPH. Parametric Portfolio Associates LLC boosted its position in shares of Amphastar Pharmaceuticals by 72.0% in the second quarter. Parametric Portfolio Associates LLC now owns 45,615 shares of the company’s stock valued at $815,000 after acquiring an additional 19,091 shares during the period. The Manufacturers Life Insurance Company boosted its position in shares of Amphastar Pharmaceuticals by 1.1% in the second quarter. The Manufacturers Life Insurance Company now owns 28,701 shares of the company’s stock valued at $512,000 after acquiring an additional 312 shares during the period. Prudential Financial Inc. boosted its position in shares of Amphastar Pharmaceuticals by 8.3% in the third quarter. Prudential Financial Inc. now owns 63,580 shares of the company’s stock valued at $1,136,000 after acquiring an additional 4,850 shares during the period. BNP Paribas Arbitrage SA boosted its position in shares of Amphastar Pharmaceuticals by 70.2% in the third quarter. BNP Paribas Arbitrage SA now owns 17,946 shares of the company’s stock valued at $321,000 after acquiring an additional 7,401 shares during the period. Finally, Municipal Employees Retirement System of Michigan boosted its position in shares of Amphastar Pharmaceuticals by 58.8% in the third quarter. Municipal Employees Retirement System of Michigan now owns 13,390 shares of the company’s stock valued at $239,000 after acquiring an additional 4,960 shares during the period. 44.46% of the stock is owned by institutional investors.
In other Amphastar Pharmaceuticals news, insider Jason B. Shandell sold 20,000 shares of the company’s stock in a transaction that occurred on Tuesday, March 20th. The stock was sold at an average price of $19.43, for a total transaction of $388,600.00. Following the completion of the sale, the insider now owns 251,372 shares of the company’s stock, valued at $4,884,157.96. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Jason B. Shandell sold 18,627 shares of the company’s stock in a transaction that occurred on Friday, January 26th. The stock was sold at an average price of $19.42, for a total value of $361,736.34. The disclosure for this sale can be found here. Insiders have sold 84,387 shares of company stock valued at $1,659,763 in the last ninety days. Company insiders own 11.10% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This article was originally reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this article on another publication, it was illegally copied and reposted in violation of U.S. & international trademark & copyright law. The correct version of this article can be accessed at https://www.dispatchtribunal.com/2018/04/07/research-analysts-offer-predictions-for-amphastar-pharmaceuticals-incs-q1-2018-earnings-amph.html.
Amphastar Pharmaceuticals Company Profile
Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses primarily on developing, manufacturing, marketing and selling generic and injectable, inhalation and intranasal products. The Company has two segments: finished pharmaceutical products and active pharmaceutical ingredients (API) products.
Get a free copy of the Zacks research report on Amphastar Pharmaceuticals (AMPH)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Amphastar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.